{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:03:00Z","timestamp":1790834580694,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T00:00:00Z","timestamp":1475884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sjogren\u2019s syndrome (SS) is a complex heterogeneous autoimmune disease resulting in loss of salivary gland and lacrimal gland function that may include multiple systemic manifestations including lymphoma. Multiple cell types participate in disease pathogenesis. This review discusses evidence for abnormal B cell subpopulations in patients with SS, critical roles of B cells in SS and the status of B cell\u2013directed therapies in the management of patients with SS.<\/jats:p>","DOI":"10.3390\/jcm5100087","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T10:35:19Z","timestamp":1476095719000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Multiple Roles for B-Lymphocytes in Sjogren\u2019s Syndrome"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-796X","authenticated-orcid":false,"given":"Julian","family":"Ambrus","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmanan","family":"Suresh","sequence":"additional","affiliation":[{"name":"Immco Diagnostics and the Department of Oral Diagnostic Sciences, SUNY at Buffalo School of Dental Science, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammon","family":"Peck","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2014.01.013","article-title":"Classification criteria of Sjogren\u2019s syndrome","volume":"48\u201349","author":"Goules","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2013-203845","article-title":"Comparison of the American-European Consensus Group Sjogren\u2019s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort","volume":"73","author":"Rasmussen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"American College of Rheumatology classification criteria for Sjogren\u2019s syndrome: A data-driven, expert consensus approach in the Sjogren\u2019s International Collaborative Clinical Alliance Cohort","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.01.001","article-title":"Sjogren\u2019s syndrome: A forty-year scientific journey","volume":"51","author":"Moutsopoulos","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sjogren\u2019s syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coms.2013.09.002","article-title":"Sjogren\u2019s Syndrome An Update on Epidemiology and Current Insights on Pathophysiology","volume":"26","author":"Reksten","year":"2014","journal-title":"Oral Maxillofac. Surg. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7861\/clinmedicine.14-2-157","article-title":"A retrospective study of long-term outcomes in 152 patients with primary Sjogren\u2019s syndrome: 25-year experience","volume":"14","author":"Abrol","year":"2014","journal-title":"Clin. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.autrev.2016.03.004","article-title":"Primary Sjogren\u2019s syndrome: Clinical phenotypes, outcome and the development of biomarkers","volume":"15","author":"Goules","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogren\u2019s syndrome and malignancy risk: A systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1073\/pnas.95.13.7538","article-title":"Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren\u2019s syndrome","volume":"95","author":"Robinson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.167.7.3610","article-title":"Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren\u2019s syndrome","volume":"167","author":"Bohnhorst","year":"2001","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.20276","article-title":"Abnormalities in peripheral B cell memory of patients with primary Sjogren\u2019s syndrome","volume":"50","author":"Hansen","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/art.38734","article-title":"Primary Sjogren\u2019s Syndrome Is Characterized by Distinct Phenotypic and Transcriptional Profiles of IgD plus Unswitched Memory B Cells","volume":"66","author":"Roberts","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cei.12703","article-title":"A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjogren\u2019s syndrome and systemic lupus erythematosus","volume":"183","author":"Szabo","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/art.10445","article-title":"Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren\u2019s syndrome","volume":"46","author":"Hansen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1002\/art.21936","article-title":"Identification of transitional type IIB cells in the salivary glands of patients with Sjogren\u2019s syndrome","volume":"54","author":"Daridon","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/adpa.2001.26980","article-title":"Extranodal marginal-zone B-cell lymphoma of the salivary gland","volume":"5","author":"Abbondanzo","year":"2001","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1080\/10428190701297386","article-title":"Nodal marginal zone B-cell lymphoma associated with Sjogren\u2019s syndrome: A report of three cases","volume":"48","author":"Kojima","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V90.2.766","article-title":"Lymphomas in patients with Sjogren\u2019s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses","volume":"90","author":"Royer","year":"1997","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjogren Syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.22458","article-title":"Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren\u2019s syndrome","volume":"56","author":"Daridon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.0105-2896.2005.00219.x","article-title":"The role of BAFF in immune function and implications for autoimmunity","volume":"204","author":"Kalled","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.180.7.5130","article-title":"CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren\u2019s syndrome and MALT lymphoma: Association with reactive and malignant areas of lymphoid organization","volume":"180","author":"Barone","year":"2008","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/art.21129","article-title":"Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren\u2019s syndrome","volume":"52","author":"Hansen","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13075-016-1006-1","article-title":"Identification of definitive serum biomarkers associated with disease activity in primary Sjogren\u2019s syndrome","volume":"18","author":"Nishikawa","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/art.1780310509","article-title":"B cells expressing CD5 are increased in Sjogren\u2019s syndrome","volume":"31","author":"Dauphinee","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_28","first-page":"239","article-title":"The role of CD5-expressing B cells in health and disease (Review)","volume":"3","author":"Pers","year":"1999","journal-title":"Int. J. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2741\/2219","article-title":"Role of B cells in Sjogren\u2019s syndrome\u2014From benign lymphoproliferation to overt malignancy","volume":"12","author":"Jonsson","year":"2007","journal-title":"Front. Biosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/1744666X.2014.891439","article-title":"B-cell hyperactivity in primary Sjogren\u2019s syndrome","volume":"10","author":"Kroese","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.4049\/jimmunol.0902391","article-title":"Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB\/W F(1) Mice","volume":"184","author":"Haas","year":"2010","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3313","article-title":"Sjogren\u2019s syndrome: Studying the disease in mice","volume":"13","author":"Delaleu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/1744666X.2014.883920","article-title":"The value of animal models to study immunopathology of primary human Sjogren\u2019s syndrome symptoms","volume":"10","author":"Donate","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-3083.2006.01828.x","article-title":"Sjogren\u2019s syndrome-like disease of C57BL\/6.NOD-Aec1Aec2 mice: Gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus","volume":"64","author":"Nguyen","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.clim.2008.10.006","article-title":"IL-14\u03b1, the nexus for primary Sjogren\u2019s disease in mice and humans","volume":"130","author":"Shen","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4049\/jimmunol.1203440","article-title":"Different Stages of Primary Sjogren\u2019s Syndrome Involving Lymphotoxin and Type 1 IFN","volume":"191","author":"Shen","year":"2013","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.4049\/jimmunol.177.8.5676","article-title":"Development of autoimmunity in IL-14\u03b1-transgenic mice","volume":"177","author":"Shen","year":"2006","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2016.04.008","article-title":"Central role for marginal zone B cells in an animal model of Sjogren\u2019s syndrome","volume":"168","author":"Shen","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.4049\/jimmunol.179.4.2318","article-title":"Development of Sjogren\u2019s syndrome in nonobese diabetic-derived autoimmune-prone C57BL\/6.NOD-Aec1Aec2 mice is dependent on complement component-3","volume":"179","author":"Nguyen","year":"2007","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/eji.200636270","article-title":"Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells","volume":"36","author":"Fletcher","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/art.21945","article-title":"Impaired salivary gland function in NOD mice\u2014Association with changes in cytokine profile but not with histopathologic changes in the salivary gland","volume":"54","author":"Jonsson","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.4049\/jimmunol.1001520","article-title":"A Role for Lymphotoxin in Primary Sjogren\u2019s Disease","volume":"185","author":"Shen","year":"2010","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2005.11.004","article-title":"Sjogren\u2019s syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease","volume":"26","author":"Gao","year":"2006","journal-title":"J. Autoimmun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.molimm.2005.09.003","article-title":"Role of complement and B lymphocytes in Sjogren\u2019s syndrome-like autoimmune exocrinopathy of NOD.B10-H2(B) mice","volume":"43","author":"Nguyen","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni1113","article-title":"The complement system in regulation of adaptive immunity","volume":"5","author":"Carroll","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.0105-2896.2004.0112.x","article-title":"Development and selection of marginal zone B cells","volume":"197","author":"LopesCarvalho","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev.immunol.23.021704.115728","article-title":"Marginal zone B cells","volume":"23","author":"Pillai","year":"2005","journal-title":"Ann. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clim.2016.01.015","article-title":"Early BAFF receptor blockade mitigates murine Sjogren\u2019s syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction","volume":"164","author":"Sharma","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0022034513483315","article-title":"Type I interferon receptor deficiency prevents murine Sjogren\u2019s syndrome","volume":"92","author":"Szczerba","year":"2013","journal-title":"J. Dent. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sjogren\u2019s syndrome\u2014A possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/1744666X.2014.876364","article-title":"Type I IFN signature in primary Sjogren\u2019s syndrome patients","volume":"10","author":"Brkic","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.172.2.812","article-title":"TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma","volume":"172","author":"Batten","year":"2004","journal-title":"J. Immunol."},{"key":"ref_55","first-page":"970","article-title":"Salivary cytokine profiles in primary Sjogren\u2019s syndrome differ from those in non-Sjogren sicca in terms of TNF-\u03b1 levels and Th-1\/Th-2 ratios","volume":"29","author":"Kang","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/smim.1998.0138","article-title":"Role of early cytokines, including alpha and beta interferons (IFN-alpha\/beta), in innate and adaptive immune responses to viral infections","volume":"10","author":"Biron","year":"1998","journal-title":"Semin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.trsl.2014.10.005","article-title":"Targeting of type I interferon in systemic autoimmune diseases","volume":"165","author":"Crow","year":"2015","journal-title":"Transl. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1007\/s10875-014-0025-4","article-title":"Natural IgM: Beneficial Autoantibodies for the Control of Inflammatory and Autoimmune Disease","volume":"34","author":"Gronwall","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.021908.132607","article-title":"Human Marginal Zone B Cells","volume":"27","author":"Weill","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1084\/jem.20050338","article-title":"Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus","volume":"202","author":"Christensen","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.30282","article-title":"Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren\u2019s syndrome","volume":"63","author":"Park","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molimm.2013.06.004","article-title":"The inhibitory effects of antimuscarinic autoantibodies in the sera of primary Sjogren syndrome patients on the gastrointestinal motility","volume":"56","author":"Park","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clim.2012.09.013","article-title":"Novel autoantibodies in Sjogren\u2019s syndrome","volume":"145","author":"Shen","year":"2012","journal-title":"Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Suresh, L., Malyavantham, K., Shen, L., and Ambrus, J.L. (2015). Investigation of novel autoantibodies in Sjogren\u2019s syndrome utilizing Sera from the Sjogren\u2019s international collaborative clinical alliance cohort. BMC Ophthalmol., 15.","DOI":"10.1186\/s12886-015-0023-1"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/gene.2015.17","article-title":"Suppression of autoimmunity by CD5(+) IL-10-producing B cells in lupus-prone mice","volume":"16","author":"Baglaenko","year":"2015","journal-title":"Genes Immun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-065X.2008.00661.x","article-title":"Regulatory B cells as inhibitors of immune responses and inflammation","volume":"224","author":"Bouaziz","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.2009.05137.x","article-title":"B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer","volume":"1183","author":"DiLillo","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.4049\/jimmunol.1400336","article-title":"A Novel Mechanism of B Cell-Mediated Immune Suppression through CD73 Expression and Adenosine Production","volume":"193","author":"Kaku","year":"2014","journal-title":"J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/BOR.0000000000000096","article-title":"Advances in the understanding and treatment of systemic complications in Sjogren\u2019s syndrome","volume":"26","author":"Grp","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/030097400447525","article-title":"Current concepts on diagnosis, autoantibodies and therapy in Sjogren\u2019s syndrome","volume":"29","author":"Jonsson","year":"2000","journal-title":"Scand. J. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32833c36c5","article-title":"Pathogenesis of Sjogren\u2019s syndrome and therapeutic consequences","volume":"22","author":"Mariette","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12016-007-8008-3","article-title":"Conventional therapy of Sjogren\u2019s syndrome","volume":"32","author":"Mavragani","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sjogren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren\u2019s syndrome: An open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Souza, F.B.D., Porfirio, G.J.M., Andriolo, B.N.G., de Albuquerque, J.V., and Trevisani, V.F.M. (2016). Rituximab Effectiveness and Safety for Treating Primary Sjogren\u2019s Syndrome (pSS): Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150749"},{"key":"ref_77","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren\u2019s syndrome: The BELISS open-label phase II study","volume":"54","author":"Quartuccio","year":"2015","journal-title":"Rheumatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: Results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren\u2019s syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/asheducation.V2000.1.394.394","article-title":"Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy","volume":"2000","author":"Waldmann","year":"2000","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: Diagnosis and treatment","volume":"80","author":"Ansell","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren\u2019s syndrome","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren\u2019s syndrome: A prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of Primary Sjogren Syndrome with Rituximab: A Randomized Trial","volume":"160","author":"Mariette","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-3083.2008.02185.x","article-title":"Anti-CD20 treatment in Primary Sjogren\u2019s syndrome","volume":"68","author":"Isaksen","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of Rituximab Treatment in Primary Sjogren\u2019s Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren\u2019s syndrome with peripheral nervous system involvement: Results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.30236","article-title":"B Cell Reconstitution and T Helper Cell Balance After Rituximab Treatment of Active Primary Sjogren\u2019s Syndrome: A Double-Blind, Placebo-Controlled Study","volume":"63","author":"Abdulahad","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12016-008-8074-1","article-title":"Rituximab: Beyond simple B cell depletion","volume":"34","author":"Kessel","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4049\/jimmunol.1401329","article-title":"B10 cells: A functionally defined regulatory B cell subset","volume":"194","author":"Tedder","year":"2015","journal-title":"J. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/5\/10\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:32:32Z","timestamp":1760211152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/5\/10\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,8]]},"references-count":91,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"alternative-id":["jcm5100087"],"URL":"https:\/\/doi.org\/10.3390\/jcm5100087","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,8]]}}}